Longeveron outlined a pivotal year ahead, confirming it remains on track to deliver top-line data in the third quarter...

Trevi Therapeutics has secured end-of-Phase 2 alignment with FDA for Haduvio (oral nalbuphine ER) in idiopathic pulmonary fibrosis (IPF)-related...

BNP Paribas flagged J&J's oral psoriasis candidate as a credible Skyrizi rival, and Wall Street mostly shrugged. They shouldn't...

CytomX Therapeutics has launched a $250 million underwritten public offering of common stock, with an additional 30-day option for...

Rhythm Pharmaceuticals reported topline results from EMANATE, a global, randomized, double-blind, placebo-controlled Phase 3 trial of setmelanotide in rare,...

Fennec Pharmaceuticals has settled its patent litigation with Cipla over a proposed generic of Pedmark, securing an agreement that...

CytomX Therapeutics reported a positive Phase 1 dose-expansion update for varsetatug masetecan, an EpCAM-targeted Probody ADC, in advanced colorectal...

Zenas Biopharma will file a U.S. BLA for obexelimab in IgG4-related disease in Q2 2026, with an EMA submission...

Akari Therapeutics has marked its first year under new leadership with a reset around antibody-drug conjugates, unveiling concrete steps...

Barinthus Biotherapeutics plans to merge with Clywedog Therapeutics in an all-stock deal expected to close in the second quarter...